Viewing data from:

DACARBAZINE

ANDA

DACARBAZINE | A070962 | ABRAXIS PHARMACEUTICAL PRODUCTS

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Dacarbazine (2023)

Total Spending

$3K

Total Claims

Beneficiaries

—

Avg Cost/Unit

$11.06

Spending Trend

$3K(2019)→$2K(2020)→$1K(2021)→$2K(2022)→$3K(2023)

YoY Change:+9.1%

5yr CAGR:+3.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Medicare Part B Spending

CMS physician-administered drug spending for Dacarbazine (2023)

Total Spending

$74K

Total Claims

2,522

Beneficiaries

396

ASP Price

—

HCPCS: J9130 — Dacarbazine, 100 mg

Source: CMS Medicare Part B Spending by Drug (2023). Shows physician-administered drug costs.

API Supply Chain2 active DMFs6 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

FUJIMOTO CHEMICALS CO LTDDACARBAZINE (BULK)

DMF 89141991

MATRIX PHARMACORP PRIVATE LTDDACARBAZINE USP

DMF 301072016

KYOWA HAKKO KOGYO CO LTDInactiveDACARBAZINE (

DMF 34571979

SOCIETE FRANCAISE D'ORGANOInactiveDACARBAZINE

DMF 47561982

KYOWA HAKKO KOGYO CO LTDInactiveDACARBAZINE

DMF 68191987

GMT FINE CHEMCALS SAInactiveDACARBAZINE USP

DMF 164112003

PLIVA LACHEMA ASInactiveDACARBAZINE

DMF 163262002

MAC CHEM PRODUCTS INDIA PVT LTDInactiveDACARBAZINE USP

DMF 256242011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 100MG/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Aug 28, 1986

No patent or exclusivity listings for this strength.